Frazier Life Sciences raises over $1.1 billion for its small-mid-cap biotech fund, total commitments now $2.8 billion

Frazier Life Sciences announced that it has added more than $1.1 billion in new capital to its public fund that targets small and mid‑size biopharma companies. The infusion brings the fund's total capital commitments to roughly $2.8 billion.

The fund, launched in 2021, is intended to help smaller drugmakers manage sector volatility and can invest in both public companies and later‑stage private firms through crossover financings.

Past beneficiaries include Verona Pharma, which was bought by Merck for $10 billion, and Carmot Therapeutics, acquired by Roche for $2.7 billion. Alpine Immune Sciences also received support before its $4.9 billion sale to Vertex Pharmaceuticals.